All Clarivate Analytics websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
Ariad Pharmaceuticals Inc. provided positive clinical data for Iclusig (ponatinib). The drug had a rocky start after receiving a December 2012 approval for use in patients with chronic, accelerated and blast phases of chronic myelogenous leukemia (CML) and Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) whose disease is resistant or intolerant to tyrosine kinase inhibitors (TKIs).